AOL Money & Finance

Immunotherapy for Prostate AdenoCarcinoma Treatment posts

Feed

Options Update: Dendreon options indicate movement into data

Dendreon (NYSE: DNDN) was halted at $7.30. DNDN is reporting top-line data from the ongoing Phase 3 IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment) this morning. DNDN April 7 straddle is priced at $1.87, May 7 straddle is priced at $6.60 according to Track Data, suggesting large price movement.

NASDAQ 100 (NASDAQ:QQQQ) overall implied volatility at 36; 26-week average is 43. CBOE Volatility Index S&P 500 Options-VIX at 37.81; 10-day moving average is 40.82.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Symbol Lookup
IndexesChangePrice
DJIA-154.4810,309.92
NASDAQ-37.612,138.44
S&P 500-19.141,091.49

Last updated: November 27, 2009: 01:55 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance